文献速递糖尿病

利用REWIND试验的推算安慰剂分析估算SURPASS-CVOT中替尔泊肽的真实MACE获益

Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND.
PubMed 文献 · Diabetes Care · 2026-01-01

本研究采用间接比较方法,将SURPASS-CVOT中替尔泊肽与度拉糖肽的MACE-3风险比乘以REWIND中度拉糖肽与安慰剂的风险比,估算替尔泊肽 versus 推算安慰剂的疗效。结果显示替尔泊肽与更低的MACE-3(HR 0.72;95%CI 0.55,0.94)、心血管死亡或心衰事件(HR 0.70;95%CI 0.51,0.96)及全因死亡(HR 0.61;95%CI 0.45,0.82)相关,敏感性分析结果基本一致。

核心结论

  • 在预设的探索性间接比较中,替尔泊肽 compared with 推算安慰剂与2型糖尿病合并动脉粥样硬化性心血管疾病患者的心血管结局和全因死亡减少相关。

研究设计与样本

  • 间接比较分析,纳入REWIND中符合SURPASS-CVOT入选条件的2,055例参与者及SURPASS-CVOT全部13,165例参与者,采用倾向性评分校正研究间差异。

主要发现

  • 替尔泊肽 versus 推算安慰剂:MACE-3 HR 0.72(95%CI 0.55,0.94)。
  • 替尔泊肽 versus 推算安慰剂:心血管死亡或心衰事件 HR 0.70(95%CI 0.51,0.96)。
  • 替尔泊肽 versus 推算安慰剂:全因死亡 HR 0.61(95%CI 0.45,0.82)。
  • 未校正分析、纳入全部REWIND人群或GLP-1RA荟萃分析数据的敏感性分析结果总体一致。

关键数值与推荐

  • 主要终点MACE-3的间接治疗效应HR为0.72(95%CI 0.55,0.94),替尔泊肽优于推算安慰剂。
  • 次要终点心血管死亡或心衰事件HR为0.70(95%CI 0.51,0.96)。
  • 全因死亡HR为0.61(95%CI 0.45,0.82)。

临床怎么用

  • 对于2型糖尿病合并动脉粥样硬化性心血管疾病的患者,替尔泊肽可能带来心血管结局和生存获益,支持其在该人群中的应用。

局限性

  • 本研究为间接比较的探索性分析,非头对头随机对照试验,结果需谨慎解读。
  • 依赖REWIND中符合条件人群的推算安慰剂效应,可能存在残余混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In prespecified analyses, the treatment effect for major adverse cardiovascular event (MACE) of tirzepatide compared with imputed placebo was estimated using SURPASS-Cardiovascular Outcomes Trial (SURPASS-CVOT) and Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) trial data. RESEARCH DESIGN AND METHODS: The indirect comparison with placebo was conducted for primary (MACE-3) and secondary outcomes of SURPASS-CVOT. The analysis included data from REWIND participants who would have been eligible for SURPASS-CVOT and all participants from SURPASS-CVOT. Propensity score estimation was used to adjust for differences in participant characteristics between studies. The indirect analysis of the treatment effect was derived by multiplying the hazard ratio (HR) for MACE-3 between tirzepatide and dulaglutide in SURPASS-CVOT by the HR for dulaglutide versus placebo in REWIND. Sensitivity analyses were performed using unadjusted analyses, including both the selected REWIND and the entire REWIND populations, and adjusted analysis in the entire REWIND population. Post hoc sensitivity analyses used data from a recent glucagon-like peptide 1 receptor agonist (GLP-1RA) meta-analysis that included REWIND. RESULTS: Analyses included 2,055 of 9,901 participants from REWIND and all 13,165 participants from SURPASS-CVOT. In indirect treatment effect comparisons, tirzepatide versus placebo was associated with lower MACE-3 (HR 0.72; 95% CI 0.55, 0.94), death from CV cause or heart failure events (HR 0.70; 95% CI 0.51, 0.96), and all-cause death (HR 0.61; 95% CI 0.45, 0.82). Sensitivity analyses, including nonadjusted or the entire REWIND cohort data or meta-analysis data for GLP-1RAs, were generally consistent. CONCLUSIONS: In this indirect prespecified exploratory comparison, tirzepatide compared with imputed placebo was associated with reduced CV outcomes and all-cause mortality in participants with type 2 diabetes and established atherosclerotic CV disease.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Sattar N, Gerstein HC, D'Alessio D, et al. Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND. Diabetes Care. 2026. PMID: 41940793. doi:10.2337/dc26-0298

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。